Screening and Treatment of Latent Tuberculosis Infection among Healthcare Workers at a Referral Hospital in Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Healthcare workers (HCWs) have a high risk of tuberculosis (TB) infection. Since August 2017, Korea has mandated the testing of latent TB infection (LTBI) and recommended treatment from HCWs at medical institutions. However, the acceptance/completion rate and adverse events of LTBI treatment have not been analyzed. Materials and Methods: From February to August 2017, we conducted a retrospective study at a referral university hospital in Korea, to screen the interferon-gamma release assay (IGRA) tests conducted for all HCWs for detecting and treating LTBI. HCWs diagnosed with LTBI were offered a 9-month isoniazid (9H), 3-month isoniazid/rifampin (3HR), or 4-month rifampin regimen. We investigated the acceptance/completion rate, adverse events, and causes of discontinuation or change in LTBI medication. A major adverse event was one wherein a patient had any adverse event ≥grade 3 causing LTBI treatment interruption. Results: Of the 1,538 HCWs, 1,379 underwent IGRA testing for LTBI. Among them, 13.6% (187/1,379) tested positive and 73.3% (137/187) received treatment. The overall completion rate was 97.8% (134/137). HCWs were significantly more likely to complete first-line therapy with 3HR than with 9H (91.4% vs. 76.7%, P = 0.02). The most common major adverse event was hepatotoxicity (n = 7), followed by thrombocytopenia (n = 1) and anaphylactic shock (n = 1). Hepatotoxicity and hepatotoxicity (≥ grade 2) were more frequent in 9H than in 3HR (39.5% vs. 17.2%, P = 0.006 and 18.6% vs. 3.7%, P = 0.005, respectively). The median time to hepatotoxicity was 96 days (interquartile range, 20 – 103 days). Conclusion: Completion of first-line therapy for LTBI is more likely with 3HR than with 9H. This might be related to the development of hepatotoxicity after around 3 months of treatment. Anaphylactic shock and platelet count should be carefully monitored in those receiving rifampin-containing regimens.
Abstract
Background: Healthcare workers (HCWs) have a high risk of tuberculosis (TB) infection. Since August 2017, Korea has mandated the testing of latent TB infection (LTBI) and recommended treatment from HCWs at medical institutions. However, the acceptance/completion rate and adverse events of LTBI treatment have not been analyzed. Materials and Methods: From February to August 2017, we conducted a retrospective study at a referral university hospital in Korea, to screen the interferon-gamma release assay (IGRA) tests conducted for all HCWs for detecting and treating LTBI. HCWs diagnosed with LTBI were offered a 9-month isoniazid (9H), 3-month isoniazid/rifampin (3HR), or 4-month rifampin regimen. We investigated the acceptance/completion rate, adverse events, and causes of discontinuation or change in LTBI medication. A major adverse event was one wherein a patient had any adverse event ≥grade 3 causing LTBI treatment interruption. Results: Of the 1,538 HCWs, 1,379 underwent IGRA testing for LTBI. Among them, 13.6% (187/1,379) tested positive and 73.3% (137/187) received treatment. The overall completion rate was 97.8% (134/137). HCWs were significantly more likely to complete first-line therapy with 3HR than with 9H (91.4% vs. 76.7%, P = 0.02). The most common major adverse event was hepatotoxicity (n = 7), followed by thrombocytopenia (n = 1) and anaphylactic shock (n = 1). Hepatotoxicity and hepatotoxicity (≥ grade 2) were more frequent in 9H than in 3HR (39.5% vs. 17.2%, P = 0.006 and 18.6% vs. 3.7%, P = 0.005, respectively). The median time to hepatotoxicity was 96 days (interquartile range, 20 – 103 days). Conclusion: Completion of first-line therapy for LTBI is more likely with 3HR than with 9H. This might be related to the development of hepatotoxicity after around 3 months of treatment. Anaphylactic shock and platelet count should be carefully monitored in those receiving rifampin-containing regimens.
참고문헌 (23)
- 이지은, "What Strategy Can be Applied to the Patients with Culture Positive Tuberculosis to Reduce Treatment Delay in a Private Tertiary Healthcare Center?", Infection and Chemotherapy, 43(1), pp.42~47 (2011), 대한감염학회
- Park HY, "Interferon-γ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital", Scand J Infect Dis, 42, pp.943~945 (2010)
- Lee K, "Annual incidence of latent tuberculosis infection among newly employed nurses at a tertiary care university hospital", Infect Control Hosp Epidemiol, 30, pp.1218~1222 (2009)
- 박세윤, "Aggressive Contact Investigation of In-Hospital Exposure to Active Pulmonary Tuberculosis", Journal of Korean Medical Science, 34(7), pp.1~8 (2019), 대한의학회
- Jensen PA, "Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005", MMWR Recomm Rep, 54, pp.1~141 (2005)
- "Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control"[URL]
- 조경욱, "Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study", Tuberculosis and Respiratory Diseases, 75(1), pp.18~24 (2013), 대한결핵및호흡기학회
- Yeon JH, "Prevalence and risk factors of latent tuberculosis among Korean healthcare workers using whole-blood interferon-γrelease assay", Sci Rep, 8, pp.10113~ (2018)
- 조경숙, "Tuberculosis control in the Republic of Korea", Epidemiology and Health, 40, pp.1~6 (2018), 한국역학회[DOI]
- Centers for Disease Control and Prevention (CDC), "Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection", MMRW Morb Mortal Wkly Rep, 60, pp.1650~1653 (2011)
- Arquello Perez E, "Management of latent tuberculosis infection among healthcare workers : 10-year experience at a single center", Clin Infect Dis, 65, pp.2105~2111 (2017)
- Lee H, "Factors associated with non-initiation of latent tuberculosis treatment among healthcare workers with a positive interferon-gamma releasing assay", Sci Rep, 9, pp.61~ (2019)
- Khanna P, "Rate of latent tuberculosis infection detected by occupational health screening of nurses new to a London teaching hospital", Infect Control Hosp Epidemiol, 30, pp.581~584 (2009)
- "CTCAE files"[URL]
- Saukkonen JJ, "An official ATS statement: hepatotoxicity of antituberculosis therapy", Am J Respir Crit Care Med, 174, pp.935~952 (2006)
- Schein YL, "Treatment completion for latent tuberculosis infection in Norway : a prospective cohort study", BMC Infect Dis, 18, pp.587~ (2018)
- Sterling TR, "Three months of rifapentine and isoniazid for latent tuberculosis infection", N Engl J Med, 365, pp.2155~2166 (2011)
- Belknap R, "Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection : a randomized trial", Ann Intern Med, 167, pp.689~697 (2017)
- Getahun H, "Latent Mycobacterium tuberculosis infection", N Engl J Med, 372, pp.2127~2135 (2015)
- Fountain FF, "Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection : a 7-year evaluation from a public health tuberculosis clinic", Chest, 128, pp.116~123 (2005)
- Park SJ, "Comparison of LTBI treatment regimens for patients receiving anti-tumor necrosis factor therapy", Int J Tuberc Lung Dis, 19, pp.342~348 (2015)
- Njie GJ, "Isoniazid-rifapentine for latent tuberculosis infection : a systematic review and meta-analysis", Am J Prev Med, 55, pp.244~252 (2018)
- Menzies D, "Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults", N Engl J Med, 379, pp.440~453 (2018)